key: cord-0876090-u3b0ekb7
authors: Ahmed, Jibran; Karass, Michael; Aujla, Amandeep; McHale, Patricia; Kretschmer, Patricia; Mazumder, Amitabha; Seiter, Karen; Ahmed, Tauseef; Lim, Seah H.; Knoll, Bettina M.
title: Late‐onset fever and engraftment syndrome following autologous stem cell transplant: Impact on resource utilization
date: 2018-08-14
journal: Am J Hematol
DOI: 10.1002/ajh.25221
sha: e8587ccc28a5e667e18c5073f4b5176d8fcffab8
doc_id: 876090
cord_uid: u3b0ekb7

nan

did not develop any post-transplant fever ( Figure 1A ). The median PT-LOS was 13 days (range 12-16; 95% CI 13-14) in the group without fever but 15 days (range 12-38; 95% CI 15-17) in the group with fever (P = 0.01). The third quartile PT-LOS in the group without fever was 14 days and with fever 20 days (P = 0.004). The difference in the PT-LOS between the two groups was predominantly due to the increased PT-LOS in those with late-onset fever ( Figure 1B ). There was no statistical difference in the PT-LOS between the group without fever and the group with early-onset fever. However, the median PT-LOS for late-onset fever was significantly longer when compared with those without fever (17 days vs. 13 days; HR 3.3; 95% CI 1.3-8.7; P = 0.002) and those with early onset fever (17 vs. 14; HR 1.7; 95% CI 0.9-3; P = 0.048).

We next determined the impact of ES on PT-LOS. We first used the following criteria for ES: The occurrence of a new fever, not associated with any microbial isolate or infection, that occurred 72 hours before or after neutrophil engraftment, and associated with a skin rash, pulmonary infiltrates, diarrhea, or new abnormal liver function tests. Twenty (27%) cases of ES occurred in this cohort of patients.

However, when we included the eight patients with noninfectious fever whose fever was probably due to ES even though the fever was not associated with any rash, diarrhea, pulmonary infiltrate, or abnormal liver function tests, the incidence of ES went up to 37%. By far, ES was the commonest cause for new fever that occurred after Day +8, being responsible for 67% of all late-onset fevers. ES resulted in significantly longer PT-LOS when compared with those without fever (P = 0.0001; HR 2.9; 95% CI 1.1-7.2; Figure 1C ). The median PT-LOS in patients with ES was 16 days (95% CI 15-20), when compared with 13 days (95% CI 13-14) in those without fever (P = 0.004). In conclusion, ES occurs frequently after autologous HPCT. ES not only increases transplant-related morbidities but also resource utilization. Identification of biomarkers that can be used to help diagnose ES is highly desirable so that these patients do not have to undergo unnecessary investigations and additional antimicrobial therapy that consequently result in longer PT-LOS and higher transplant costs. Elevation of C-reactive protein (CRP) has been found to be associated with ES. 6 However, CRP is highly nonspecific and is also elevated in sepsis, the very complication that requires aggressive antimicrobial therapy in this group of immunocompromised patients.

Serum procalcitonin is a robust biomarker for sepsis. Future studies may examine the combination of CRP and procalcitonin in the diagnosis of ES and exclusion of sepsis, so patients with a low procalcitonin that accompanies an elevated CRP be confidently diagnosed ES and be spared the additional investigations and prolonged courses of intravenous antimicrobial therapy for the symptoms associated with ES.

http://orcid.org/0000-0003-1449-7794

Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients

To the Editor:

Chelation therapy to treat iron overload has beneficial impact on the prognosis of patients with transfusion-dependent thalassemia (TDT).

Three different chelating agents are currently available: deferoxamine (DFO) which is given subcutaneously, and two oral agents, deferasirox (DFX) and deferiprone (DFP).

in patients with severe iron burden, or for those in which monotherapy is not adequately effective. Combination of DFO and DFP is well established as a treatment for severe iron overload in heart dysfunction. 1 More recently, the combination of DFO and DFX has been shown to be safe and efficacious in treating iron overload in TDT patients nonresponder to standard treatment regimens. 2 Successful combination therapy with DFX and DFP has been reported previously, 3 as being effective in reducing iron overload and superior in improving cardiac T2*, compliance and patient satisfaction compared with the deferoxamine/deferiprone combination. 4 The use of combination therapy to address intolerance to monotherapy is not common practice, due to the expectations that patients will continue to exhibit similar or worse lack of tolerance. Some TDT patients do not tolerate either mono or combined therapy, resulting in worsening iron overload and in poor prognosis in term of life expectancy. The median adherence, calculated as the percentage of drug taken in respect to the one issued, was 90%. Median iron intake from blood transfusions was 9.9 mg/year. Mean follow-up was 52 months (ranging from 12 to 104). The mean value of serum ferritin was 1632 at baseline and

Engraftment syndrome in autologous marrow and peripheral stem cell transplantation

Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria

Engraftment syndrome following hematopoietic stem cell transplantation

Periengraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation

Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity

Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation